ライフサイエンスコーパス: polio

1 disposal of all OPV after the eradication of polio.

2 three districts of Pakistan at high risk of polio.

3 red globally by epidemics of vaccine-derived polio.

4 ncreased with a higher rate of reporting non-polio acute flaccid paralysis (AFP) (OR = 1.13, 95% CI 1

5 5% CI 1.02-1.26 for a 1-unit increase in non-polio AFP per 100,000 persons aged <15 years).

6 against risk of vaccine-associated paralytic polio and circulating vaccine-derived poliovirus.

7 $1.61 billion for the global eradication of polio and has committed to provide an additional $35 mil

8 controlled infections including smallpox and polio and that simple, effective treatment is not suffic

9 s that result in various diseases, including polio and the common cold.

10 The greatest reductions were noted for polio and tuberculosis at -3594 (95% CI -4811 to -2377;

11 such as tuberculosis, malaria, cholera, and polio, and biological threats, such as anthrax and plagu

12 er doses of acellular pertussis, inactivated polio, and diphtheria vaccines at 12 to 24 months of age

13 diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib)

14 ived polio vaccines per group assignment and polio antibody titre results to serotypes 1, 2, and 3 at

15 Nine polio areas of expertise were applied to broader immuniz

16 coverage cannot be attributed to the use of polio assets alone, 6 out of the 10 focus countries impr

17 rawal of its type 2 component, and (3) using polio assets to strengthen immunization systems in 10 pr

18 ude strengthening immunization systems using polio assets, introducing inactivated polio vaccine (IPV

19 Less time was spent on polio-associated activities in countries that had alread

20 itiative has reduced the global incidence of polio by 99% and the number of countries with endemic po

21 SMNet was created as a strategy to eradicate polio by engaging >7000 frontline social mobilizers to a

22 n teams provided significant feedback during polio campaigns and enabled supervisors to evaluate perf

23 Overall, in Pakistan the risk of polio cases was predicted to reduce between July-Decembe

24 To minimize risk of vaccine-derived polio countries using OPV were asked to dispose of all u

25 013-2018 (Endgame Plan) was developed to end polio disease.

26 akistan faces huge challenges in eradicating polio due to widespread poliovirus transmission and secu

27 e obvious similarities in strategies between polio elimination and measles and rubella elimination in

28 strategies in public health for its role in polio elimination in India.

29 The deputy incident manager of the National Polio Emergency Operations Centre was appointed the inci

30 nment engagement, and the establishment of a Polio Emergency Operations Centre.

31 helpful in supporting further stages of the polio end game and other time-sensitive vaccine introduc

32 : Despite the challenges associated with the polio end-game in high-risk, conflict-affected areas of

33 resources to provide technical assistance to polio-endemic countries.

34 campaigns in insecure and conflict-affected polio-endemic districts of Pakistan.

35 We review the lessons learned during the polio endgame about the role of subpopulations in sustai

36 ts by global partners to successfully launch polio endgame activities to permanently secure and susta

37 tant role in effective implementation of the polio endgame strategy and the national immunization str

38 public health and called for a comprehensive polio endgame strategy.

39 untries and confirms the availability of non-polio enterovirus data in the region.

40 and the disease appears to be caused by non-polio enterovirus infection, posing a major public healt

41 Non-polio enterovirus infections are not notifiable in most

42 Epidemiologic evidence suggests non-polio enteroviruses (EVs) are a potential etiology, yet

43 study highlights the wide circulation of non-polio enteroviruses in Europe, mostly affecting young ch

44 maintenance of population immunity in a post-polio era.

45 obal Polio Eradication Initiative (GPEI) for polio eradication activities (hereafter, "GPEI-funded pe

46 Rotary volunteers have provided support for polio eradication activities and continue to this day by

47 overnments and immunization professionals to polio eradication and an exemplary partnership between t

48 The Polio Eradication and Endgame Strategic Plan (PEESP) est

49 ed polio vaccine (IPV) as part of the Global Polio Eradication and Endgame Strategic Plan (the Endgam

50 The Polio Eradication and Endgame Strategic Plan 2013-2018 (

51 oral polio vaccine (OPV) associated with the Polio Eradication and Endgame Strategic Plan 2013-2018 b

52 The Polio Eradication and Endgame Strategic Plan 2013-2018 c

53 The Polio Eradication and Endgame Strategic Plan 2013-2018 w

54 to coordinate and oversee objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018,

55 The requirements under objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018-t

56 The Polio Eradication and Endgame Strategic plan outlines th

57 the necessary financial resources within the Polio Eradication and Endgame Strategic Plan timelines.

58 al partners to national staff as part of the Polio Eradication and Endgame Strategic Plan, 2013-2018.

59 ement and coordination of Objective 2 of the Polio Eradication and Endgame Strategic Plan.

60 The final stages of polio eradication are proving more difficult than the ea

61 y be drawn upon when bOPV is withdrawn after polio eradication but also could be relevant for other g

62 e STOP program and how it has contributed to polio eradication by building global public health workf

63 e Global Commission for the Certification of Polio Eradication certified the eradication of type 2 wi

64 We aimed to project economic costs of polio eradication compared to permanent control.

65 h high coverage represents the root cause of polio eradication delays.

66 public health workforce capacity to support polio eradication efforts, including national STOP progr

67 e, Nigeria has been the focus of intensified polio eradication efforts.

68 applied to a global public health issue, the polio eradication Endgame plan.

69 tor immunization-system strengthening in the Polio Eradication Endgame Strategic Plan 2013-2018 (PEES

70 d health goals in ten focus countries of the Polio Eradication Endgame Strategic Plan: policy & strat

71 ccine (IPV) represents a crucial step in the polio eradication endgame.

72 tly secure and sustain the enormous gains of polio eradication forever.

73 ventable diseases that will endure after the polio eradication goal is achieved.

74 A key strategy for polio eradication has been the development of a skilled

75 ty systems are critical for all programs and polio eradication has illustrated these can be leveraged

76 tiative (GPEI) in certifying and maintaining polio eradication in a standardized, ongoing, and credib

77 rams in Africa that have benefitted from the polio eradication infrastructure.

78 personnel receiving funding from the Global Polio Eradication Initiative (GPEI) for polio eradicatio

79 The Global Polio Eradication Initiative (GPEI) has been in operatio

80 k of independent bodies to assist the Global Polio Eradication Initiative (GPEI) in certifying and ma

81 s and setbacks in the 28 years of the Global Polio Eradication Initiative (GPEI), this article articu

82 ) is a fundamental cornerstone of the global polio eradication initiative (GPEI).

83 apacity as procurement agency for the Global Polio Eradication Initiative and Gavi, the Vaccine Allia

84 levant human resources and their role in the Polio Eradication Initiative and in RI.

85 d Somalia developed draft plans to integrate Polio Eradication Initiative assets, staff, structure, a

86 ation Systems Management Group of the Global Polio Eradication Initiative has been useful to the NVI

87 The Global Polio Eradication Initiative has built an extensive infr

88 Despite major setbacks, the Global Polio Eradication Initiative has made substantial progre

89 The Global Polio Eradication Initiative has reduced the global inci

90 Strategic Plan 2013-2018 (PEESP), the Global Polio Eradication Initiative identified 1 indicator: 10%

91 The Polio Eradication Initiative in Nigeria, which started >

92 o (STOP) program began supporting the Global Polio Eradication Initiative in the Republic of South Su

93 As the global polio eradication initiative prepares to cease use of or

94 elays in implementing the switch, the Global Polio Eradication Initiative provided catalytic financia

95 one of the key criteria prompting the Global Polio Eradication Initiative to begin withdrawal of oral

96 enter, demonstrating the value of the Global Polio Eradication Initiative's legacy.

97 ancial Resource Requirements from the Global Polio Eradication Initiative, as well as vaccination and

98 World Health Assembly established the Global Polio Eradication Initiative, which consisted of a partn

99 nd accurate laboratory results to the Global Polio Eradication Initiative.

100 liovirus type 2 during the next phase of the polio eradication plan.

101 For WHO's polio eradication programme, the addition of one IPV dos

102 f global measles and rubella elimination and polio eradication strategies.

103 has enabled implementation of the endgame of polio eradication which calls for a phased withdrawal of

104 The partnerships that helped support polio eradication will need to consider funding to maint

105 relevant (policy and technical) documents on polio eradication, along with minutes and reports from c

106 o incorporate important lessons learned from polio eradication, and polio resources are concentrated

107 uild demand and trust for the last stages of polio eradication, as well as for other life-saving heal

108 nal, and international advocacy programs for polio eradication, assisting at immunization posts and c

109 when all OPVs are completely withdrawn after polio eradication, but also may offer a useful model for

110 y provides a substantial challenge to global polio eradication, having contributed to 73% of reported

111 espite increased efforts and spending toward polio eradication, it has yet to be eliminated worldwide

112 for poliovirus is increasingly important for polio eradication, often detecting circulating virus bef

113 Given the momentum gained toward polio eradication, these resources seem well positioned

114 introduced in mass campaigns to help achieve polio eradication.

115 engthening immunization programs, other than polio eradication.

116 illance is vital for global certification of polio eradication.

117 iovirus endgame and efforts to ensure global polio eradication.

118 accine (OPV) poses a significant obstacle to polio eradication.

119 tion as we approach the endgame strategy for polio eradication.

120 xcrete vaccine-derived polioviruses threaten polio eradication.

121 Polio; eradication; transmission; heterogeneity.

122 ng further evidence for a causal role of non-polio EVs in AFM.

123 panel of EVs, including rhinoviruses and non-polio EVs increasingly linked to severe neurological dis

124 amined the effect of spatial coupling on the polio extinction frequency in islands relative to larger

125 We found polio fadeout frequency to depend on both population siz

126 coverage in polio high-risk districts of 10 polio focus countries.

127 ication of poliovirus and the elimination of polio for all time.

128 Despite Israel's having been declared polio-free in 1988, a routine sewage surveillance progra

129 tern Pacific Region (WPR) has maintained its polio-free status since 2000.

130 ntire country including Afghanistan attain a polio-free status.

131 ved polioviruses is essential for creating a polio-free world, and eliminating that risk will require

132 To secure a polio-free world, the live attenuated oral poliovirus va

133 LPs, could be ideal candidate vaccines for a polio-free world.

134 eam some of the functions, to keep the world polio-free.

135 99% and the number of countries with endemic polio from 125 to 3 countries.

136 Eliminating the risk of polio from vaccine-derived polioviruses is essential for

137 As polio funding declines, it is time to take stock of the

138 e stock of the resources made available with polio funding in Africa and begin to find ways to keep s

139 By 2016, the annual incidence of polio had decreased by >99.9%, compared with 1988, and a

140 Its unwavering commitment to eradicate polio has been vital to the success of the program.

141 tussis-containing vaccine (DTP3) coverage in polio high-risk districts of 10 polio focus countries.

142 y-based health and immunisation camps during polio immunisation campaigns was successful in increasin

143 hingya in Cox's Bazar, Bangladesh, to assess polio immunity and inform vaccination strategies.

144 routine sewage surveillance program detected polio in 2013.

145 The legacy of polio in Africa goes far beyond the tragedies of million

146 The effect of climate variables on polio incidence was negligible, indicating that a climat

147 on coverage were the strongest predictors of polio incidence, however their relative effect sizes wer

148 gement of youth groups has a great future in polio interruption as we approach the endgame strategy f

149 When polio is finally gone, we will have the knowledge from t

150 The Global Polio Laboratory Network (GPLN) began building in the la

151 As an example of how the polio legacy can create long-lasting improvements to pub

152 important piece in the documentation of the polio legacy in the Americas.

153 As part of polio legacy planning, we recommend the DDM as a model f

154 se (HFMD), with virulent variants exhibiting polio-like acute flaccid paralysis and other central ner

155 Acute flaccid myelitis (AFM) is a disabling, polio-like illness mainly affecting children.

156 predicting future cases, at a time when the polio map is shrinking.

157 ccine-preventable diseases (VPDs), including polio, measles and rubella, yellow fever, Japanese encep

158 se outbreak period, vaccination coverage for polio, measles, and yellow fever continued to decrease,

159 The incubation period for typhoid, polio, measles, leukemia and many other diseases follows

160 , Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine an

161 st-vaccination serum samples were tested for polio-neutralizing antibodies.

162 The National Stop Transmission of Polio (NSTOP) program was collaboratively established in

163 Paralytic polio once afflicted almost half a million children each

164 2, have been developed to respond to ongoing polio outbreaks due to circulating vaccine-derived type

165 In June 2014, the Polio Oversight Board (POB) agreed to make available a m

166 n and poliomyelitis, it can be used to study polio pathogenesis and to assess the efficacy of candida

167 n and poliomyelitis, it can be used to study polio pathogenesis, candidate antiviral drugs, and the e

168 e, a clinical observation first described in polio patients and stroke victims.

169 engaged with communities, and taken care of polio patients.

170 livery, and receipt of five infant vaccines: polio, pentavalent (diphtheria, tetanus, pertussis, hepa

171 The analysis illustrates that polio personnel in Northern Nigeria are used in increasi

172 The reports supported other polio program activities, such as review of microplans a

173 The new maps are useful to and used by the polio program as well as other public health programs wi

174 for more effective planning and analysis of polio program data.

175 ed a response to the outbreak relying on the polio program experiences and infrastructure.

176 the World Health Organization (WHO)-Nigeria polio program staff, as well as the program itself.

177 The legacy of the polio program will be the complete eradication of poliov

178 rnal statistician (1:1:1) to receive routine polio programme activities (control, arm A), additional

179 w epidemics represents a significant risk of polio re-emergence should immunization cease.

180 A narrative analysis of polio-related program and other official documents was c

181 The types of non-polio-related tasks performed by GPEI-funded personnel v

182 Nigeria is among the 3 countries in which polio remains endemic.

183 dation, UK Medical Research Council, and WHO Polio Research Committee.

184 lessons learned from polio eradication, and polio resources are concentrated in the countries with t

185 ine immunization in countries with extensive polio resources, and initiating activities to transition

186 ces, and initiating activities to transition polio resources, program experience, and lessons learned

187 Here we devised a strategy based on the polio:rhinovirus chimera PVSRIPO, devoid of viral neurop

188 f the states that commenced the provision of polio, RI, and other selected PHC services using the ded

189 Rohingya children had immunity gaps to all 3 polio serotypes and should be targeted by future campaig

190 As part the 2012 Nepal measles-rubella and polio SIA, we developed an intervention package designed

191 wild poliovirus serotypes causing paralytic polio since the beginning of recorded history.

192 cy collaborations and initiatives beyond the polio sphere.

193 deal" (54% vs 9%), if they do not know that polio spreads through contaminated water (41% vs 14%), o

194 Polio staff and resources are already connected with tho

195 e side, which includes the many well-trained polio staff who have vaccinated children, conducted surv

196 llance, laboratory, and other data to assess polio status in the country (NCC), World Health Organiza

197 2009, the international Stop Transmission of Polio (STOP) program began supporting the Global Polio E

198 In 1999, the Stop Transmission of Polio (STOP) program was developed and initiated by the

199 to April 2014 to the outcomes of subsequent polio supplemental immunization activities using used pr

200 atic progress was registered in the areas of polio supplementary immunization activities, acute flacc

201 ty-challenged states improved the quality of polio surveillance during the review period.

202 Cases of post-polio syndrome, type 1 diabetes, and chronic cardiomyopa

203 (polioviruses) were associated with the post-polio syndrome, while members of the B species were foun

204 In 2013, the Polio Technical Advisory Group recommended that South Su

205 lasting improvements to public health beyond polio, the Centers for Disease Control and Prevention wi

206 orld Health Assembly resolution to eradicate polio, the government of Nigeria, with support from part

207 and activities beyond those associated with polio, the training they have received to conduct tasks

208 It has brought polio to the brink of eradication.

209 ing all of the countries at highest risk for polio transmission (Afghanistan, Pakistan, Somalia, and

210 Understanding the determinants of polio transmission and its large-scale epidemiology rema

211 in districts of Afghanistan at high risk for polio transmission and to examine what knowledge, attitu

212 approach highlights the heterogeneity among polio transmission determinants.

213 VCMs) became a key strategy for interrupting polio transmission in the high-risk areas.

214 key covariates of geographical variation in polio transmission patterns by relating country-specific

215 3 months in the settlements at high risk for polio transmission with a RI card seen, from 23% to 56%,

216 he targeting of settlements at high risk for polio transmission with routine immunization (RI) and ot

217 of computer-generated models for predicting polio transmission.

218 healthy infants aged 6 weeks, not previously polio vaccinated, were allocated after computer-generate

219 k focused initially on generating demand for polio vaccination but later expanded its messaging to pr

220 ess the risk of Sabin 2 transmission after a polio vaccination campaign with a monovalent type 2 oral

221 erational tactics that have led to increased polio vaccination coverage among populations living in d

222 pplications including influenza vaccination, polio vaccination, and diabetes are discussed in this re

223 rs with documented history of at least three polio vaccinations, including OPV in the phase 4 study a

224 ek-old full-term infants due for their first polio vaccinations, who were healthy on physical examina

225 valent oral polio vaccine with bivalent oral polio vaccine ("the switch").

226 t oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) ("the switch") presented an unprece

227 April, 2016, by bivalent types 1 and 3 oral polio vaccine (bOPV) and one dose of inactivated polio v

228 t oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) has constituted an effort without p

229 ned to receive tOPV (n = 315) or inactivated polio vaccine (IPV) (n = 299) at 39 weeks.

230 synchronized introduction of the inactivated polio vaccine (IPV) and the switch from trivalent oral p

231 da and Indonesia have introduced inactivated polio vaccine (IPV) as part of the Global Polio Eradicat

232 nity through the introduction of inactivated polio vaccine (IPV) in combination with OPV.

233 coordinated efforts to introduce inactivated polio vaccine (IPV) into all countries that did not yet

234 Albania introduced inactivated polio vaccine (IPV) into its immunization system in May

235 Kano State, Nigeria, introduced inactivated polio vaccine (IPV) into its routine immunization (RI) s

236 nly introduce at least 1 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules

237 troduction of at least 1 dose of inactivated polio vaccine (IPV) into the routine immunization progra

238 PV) introduce at least 1 dose of inactivated polio vaccine (IPV) into their routine immunization sche

239 o vaccine (bOPV) and one dose of inactivated polio vaccine (IPV) where available.

240 using polio assets, introducing inactivated polio vaccine (IPV), and replacing trivalent oral polio

241 and some vaccines, including the inactivated polio vaccine (IPV), must be injected more than once for

242 hrough routine immunization with inactivated polio vaccine (IPV), to ensure type 2 immunity.

243 are key challenges in the use of inactivated polio vaccine (IPV).

244 9 northern hemisphere IIV3 or an inactivated polio vaccine (IPV).

245 ation campaign with a monovalent type 2 oral polio vaccine (mOPV2).

246 hat all countries and territories using oral polio vaccine (OPV) "switch" from trivalent OPV (tOPV; t

247 ity buy-in, to increase the coverage of oral polio vaccine (OPV) and other routine immunisations, and

248 The phased withdrawal of oral polio vaccine (OPV) associated with the Polio Eradicatio

249 The attenuated oral polio vaccine (OPV) has enabled world-wide vaccination e

250 ion initiative prepares to cease use of oral polio vaccine (OPV) in 2020, there is increasing interes

251 o the switch from trivalent to bivalent oral polio vaccine (OPV) in the 11 countries of the World Hea

252 ended that all 126 countries using only oral polio vaccine (OPV) introduce at least 1 dose of inactiv

253 es (VDPVs), however, remains a risk, as oral polio vaccine (OPV) is still used in many of the region'

254 relies on vaccination of children with oral polio vaccine (OPV) many times a year until the age of 5

255 ll and demands that all countries using Oral Polio Vaccine (OPV) only introduce at least 1 dose of In

256 ization programs of all countries using oral polio vaccine (OPV) only.

257 d polioviruses through evolution of the oral polio vaccine (OPV) poses a significant obstacle to poli

258 ude high vaccination coverage with live oral polio vaccine (OPV), surveillance for acute flaccid para

259 for quality control of live-attenuated oral polio vaccine (OPV).

260 nt was removed from the live-attenuated oral polio vaccine (OPV).

261 the inactivated polio vaccine-with the oral polio vaccine (OPV).

262 of tetanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3 months later; BCG and Tdap combin

263 Following vaccination with trivalent oral polio vaccine (tOPV) at 6, 10, and 14 weeks, infants wer

264 The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOP

265 ine (IPV) and the switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOP

266 Trivalent oral polio vaccine (tOPV) was replaced worldwide from April,

267 daily intradermal injections of inactivated polio vaccine according to six different delivery profil

268 simultaneously cease use of the type 2 oral polio vaccine and recommended that all countries and ter

269 rom trivalent (tOPV) to bivalent (bOPV) oral polio vaccine at the national-level and 3 provinces (Bal

270 which calls for a phased withdrawal of oral polio vaccine beginning with the type 2 component, intro

271 c for antigens in rotavirus vaccine and oral polio vaccine containing poliovirus serotypes 1 and 3 we

272 ul in increasing vaccine coverage, including polio vaccine coverage.

273 Introduction of inactivated polio vaccine creates challenges in maintaining the cold

274 ning vaccine and introduction of inactivated polio vaccine in routine immunization to mitigate agains

275 nd transportation capacity after inactivated polio vaccine introduction, but temperature fluctuations

276 Today, acceptance of oral polio vaccine is the highest ever.

277 vaccine (IPV), and replacing trivalent oral polio vaccine with bivalent oral polio vaccine ("the swi

278 ised children (receiving BCG, three doses of polio vaccine, three doses of pentavalent vaccine, and m

279 argest effects were observed for inactivated polio vaccine, where 2-fold higher maternal antibody con

280 his noninferiority trial was conducted among polio vaccine-naive Cuban infants who received 2 IPV dos

281 ildren-who had only received the inactivated polio vaccine-with the oral polio vaccine (OPV).

282 evious vaccinations other than BCG, and oral polio vaccine.

283 lio vaccines (OPV), and injected inactivated polio vaccines (IPV) has almost achieved global eradicat

284 Use of oral live-attenuated polio vaccines (OPV), and injected inactivated polio vac

285 ation Initiative to begin withdrawal of oral polio vaccines (OPV), beginning with the type 2 componen

286 t risk will require stopping use of all oral polio vaccines (OPVs) once all types of wild polioviruse

287 gic plan outlines the phased removal of oral polio vaccines (OPVs), starting with type 2 poliovirus-c

288 generate a meaningful policy dialogue about polio vaccines and routine immunization at multiple leve

289 or the quality assessment of next-generation polio vaccines and, eventually, for other live-attenuate

290 art of the performance of rotavirus and oral polio vaccines in developing countries (PROVIDE) study.

291 h the Manhattan Project, penicillin, and the polio vaccines in the 20th century.

292 on-to-treat population (infants who received polio vaccines per group assignment and polio antibody t

293 asing role of the dedicated mobile teams and polio VCMs in strengthening RI.

294 factor VIII heavy chain [FVIII HC]) and 59 (polio VIRAL CAPSID PROTEIN1 [VP1]) rare codons; replacem

295 d for IPV use in campaigns to interrupt wild polio virus and to control type 2 vaccine derived polio

296 virus and to control type 2 vaccine derived polio virus outbreaks, IPV supplies are severely constra

297 ed the same methodology to the West Nile and Polio virus, which demonstrated trivial connectivity wit

298 s almost achieved global eradication of wild polio viruses.

299 t decreases occurred for all vaccines except polio, with the trend of monthly decreases in the number

300 Eradication of polio would likely be cost-saving compared to permanent